Berkshire's $18B Buying Spree Just Broke My Bearish Call - Upgrading BRK-B

Berkshire's recent deals shift the thesis from cash pile to capital deployment

I'm upgrading BRK-B from Hold to Buy.

After years of watching Berkshire Hathaway set cash aside, the market is now seeing real asset buying again. This time, the moves are concrete: Berkshire has completed its purchase of OxyChem for $9.7 billion in cash and entered a definitive agreement to acquire Taylor Morrison for approximately $8.5 billion. That is roughly $18 billion of capital in motion, which matters because closed or agreed deals are easier to evaluate than future investment promises.

These are also tangible businesses. OxyChem makes PVC, chlor-alkali and related chemicals used in construction and healthcare, while Taylor Morrison is a homebuilder, not some opaque financial vehicle. On the surface, these are simple models with clear demand.

The old bear case still exists in theory: Berkshire still held $397 billion in cash. But that cash cushion may have been the setup rather than the end state. In Greg Abel's first full year as CEO, the operating signal appears to be deploying into solid assets and letting $11.35 billion of quarterly operating earnings continue fueling the company.

OxyChem and Taylor Morrison point to a preference for simple, cash-generative assets

The clearest takeaway from these moves is that Berkshire is leaning toward businesses investors can actually picture.

OxyChem looks like a clean operating purchase

OxyChem is a major producer of PVC, chlor-alkali and chlorinated organic chemicals with operations in the US, Canada, and Latin America, and Berkshire agreed to buy the segment for $9.7 billion. Importantly, another Occidental subsidiary retained OxyChem's legacy environmental liabilities, while another unit oversaw existing remedial projects. That structure suggests Berkshire wanted the operating asset rather than a legacy cleanup problem.

Taylor Morrison adds familiar housing exposure

Berkshire agreed to buy Taylor Morrison for approximately $8.5 billion in an all-cash deal at $72.50 per share, about a 24% premium to the last close. Paying that premium suggests Berkshire wanted a known quantity now instead of waiting indefinitely for a better story.

These are not abstract financial structures. OxyChem produces standardized chemicals on a large scale for water treatment, pharmaceuticals, healthcare, and residential and commercial construction. Taylor Morrison is housing, plainly stated. Berkshire is adding useful operating businesses with recognizable products and customer bases.

That matters because Berkshire is adding these assets to a portfolio that already includes chemical producer Lubrizol and freight railroad BNSF. The appeal here is not novelty; it is straightforward cash generation and durable operating assets.

Japan adds a second data point, but one stretch is not final proof

Skeptics can fairly argue that one strong stretch is not proof of a permanent strategy shift. That is fair. Still, the same preference for stable, cash-generative assets shows up elsewhere. In Japan, Berkshire has continued to deploy capital through strategic tie-ups focused on trading houses and cash-generative businesses, consistent with a broader emphasis on stability and shareholder returns.

The key watchpoint is not whether Berkshire spent money once. It is whether this becomes a repeatable pattern of buying practical assets at sensible prices.

Why BRK-B looks more compelling even if the valuation is only fair

Berkshire remains a massive, defensive holding company. But the market may not fully price what these deals change: the company is adding more everyday, cash-generating businesses on top of an engine that already produced $11.35 billion of quarterly operating earnings. At roughly $489.46 for BRK-B and about 14.6x trailing earnings, the stock is not cheap in an absolute sense. But it is not obviously expensive for a business with 19% net margins and a defensive risk profile.

The bull case: stronger earnings engine at a fair price

The bullish case is straightforward. Berkshire is buying plain-English businesses rather than trying to rescue fragile ones. OxyChem is a major producer of PVC, chlor-alkali and chlorinated organic chemicals, and Taylor Morrison is a well-known homebuilder acquired for approximately $8.5 billion. Added to existing operating businesses such as Lubrizol and BNSF, those deals expand Berkshire's real-world earnings base.

That matters because Berkshire has already shown internal growth momentum: Q1 2026 operating earnings $11.35B (+18% YoY) and insurance underwriting +28%. If capital deployment continues to add durable cash streams instead of leaving money idle, the stock could rerate through earnings power even without a dramatic drop in valuation.

The bear case: limited margin of safety and housing risk

The bearish pushback is also reasonable. The same source that highlights Berkshire's operating strength lists a DCF-implied intrinsic range of $408–$611, which suggests roughly a 4% margin of safety at the top end. In plain English, this looks more like a fair price than a fire sale.

There are two near-term caveats. First, the OxyChem purchase and Taylor Morrison agreement are only a start; they do not yet prove a lasting strategic shift. Second, Taylor Morrison brings homebuilding exposure into the mix, and housing is cyclical. If housing weakens, investors may care less how solid the rest of Berkshire looks.

What would confirm or invalidate the upgrade

What to watch - Additional evidence that this is a pattern, not a one-off, through strategic tie-ups in Japan or further U.S. acquisitions. - Continued strong core results after a quarter with +18% YoY operating earnings growth. - Smooth integration under existing management, including OxyChem president and CEO Wade Alleman and the Taylor Morrison team.

Invalidation signals - The buying activity stalls after these $9.7 billion and $8.5 billion deals. - Homebuilding softness begins to weigh on consolidated results. - The stock moves well above the top end of the $408–$611 intrinsic range without matching earnings progress.

For me, that still supports a Buy rating. You are not getting a deep discount, but you are paying for real businesses with real utility and an earnings engine that may be worth more than the market currently assigns.